Khảo SÁT việc điều TRỊ viêm phổi MẮC phải cộng đồng TẠI bệnh viện ĐA khoa KHU VỰC HÓC MÔN
Abstract
The treatment of community-acquired pneumonia (CAP) has become increasingly challenging due to the growing antimicrobial resistance among bacterial pathogens. Rational antibiotic use is a key determinant of treatment effectiveness in patients with CAP. To investigate antimicrobial resistance patterns and antibiotic utilization in the treatment of communityacquired pneumonia at Hoc Mon Regional General Hospital. A descriptive cross-sectional study was conducted using 270 medical records of hospitalized patients diagnosed with communityacquired pneumonia at Hoc Mon Regional General Hospital from July 2024 to September 2024. The median age of patients was 69 years (interquartile range, 59–77), with 65.2% aged over 65 years. Gram-negative bacteria accounted for 93.2% of isolated pathogens, predominantly Klebsiella pneumoniae (24.1%) and Pseudomonas aeruginosa (15.5%). Klebsiella pneumoniae demonstrated susceptibility rates ranging from 70% to 100% to beta-lactam/beta-lactamase inhibitor combinations. Pseudomonas aeruginosa showed high susceptibility rates (89–100%). The most commonly prescribed empirical antibiotics were ceftriaxone (51.9%) and levofloxacin (40.4%). Overall appropriateness of empirical antibiotic therapy was 41.5%. Older patients, higher Charlson score, higher CURB-65 score, and ICU admission were factors associated with treatment failure. The antibiotics recommended for the treatment of community-acquired pneumonia remain largely effective against common…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.